Leigh Baldwin & CO. LLC Takes $534,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Leigh Baldwin & CO. LLC acquired a new stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 9,443 shares of the biopharmaceutical company's stock, valued at approximately $534,000.

Other hedge funds have also recently bought and sold shares of the company. Polar Asset Management Partners Inc. purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $16,651,000. Hall Capital Management Co. Inc. purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth about $329,000. Ameriflex Group Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter worth about $322,000. Ascent Group LLC boosted its stake in Bristol-Myers Squibb by 37.9% in the fourth quarter. Ascent Group LLC now owns 44,469 shares of the biopharmaceutical company's stock valued at $2,515,000 after acquiring an additional 12,227 shares during the last quarter. Finally, Aurdan Capital Management LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $566,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY traded up $0.35 on Friday, reaching $48.20. The company's stock had a trading volume of 5,574,519 shares, compared to its average volume of 13,294,982. The company has a 50-day simple moving average of $50.71 and a 200 day simple moving average of $55.46. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market cap of $98.08 billion, a P/E ratio of -10.90, a PEG ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($4.40) earnings per share. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 5.15%. Bristol-Myers Squibb's payout ratio is 92.88%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Piper Sandler assumed coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Finally, UBS Group reduced their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.